DUBLIN, July 30, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the election of Catherine Angell Sohn, Pharm.D., CLP, to its board of directors at the company's annual meeting of shareholders held on July 27, 2012.
"Cathy has extensive product and business development experience and brings a strong patient-focused perspective to our board," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals. "As we strengthen our operations in both the United States and Europe, continue to optimize our commercial activities and evaluate product development strategies for the future, Cathy will add tremendous value."
Catherine Angell Sohn, Pharm.D., CLP, is the founder of Sohn Health Strategies where she consults for pharmaceutical, biotechnology, medical device, and consumer healthcare companies in the areas of business strategy, business development and strategic product development. She currently serves on the boards of Ariel Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, and The Dohmen Company, a privately held provider of business services to life science companies. She also serves on the Dean's Advisory Council for Drexel University School of Public Health, the Ben Franklin Technology Partners Investment Advisory Committee, Ernst & Young's global Life Science Advisory Board, Springboard Enterprises Life Science Council and the global advisory board of the Healthcare Businesswomen's Association.
From 1982 to 2010, Dr. Sohn was with GlaxoSmithKline plc (and with SmithKline Beecham plc before its merger with GlaxoWellcome plc), where she served most recently as senior vice president, worldwide business development and strategic alliances in the GSK Consumer Healthcare division. Previously, she held a series of positions in medical affairs, pharmaceutical business development, U.S. product marketing, and global strategic product development in the pharmaceutical division. She also previously served on the boards of multiple non-profit organizations, including two terms on the Health Advisory Board for the Johns Hopkins University Bloomberg School of Public Health and as vice chair of the Corporate Executive Board of the Philadelphia Museum of Art.
Dr. Sohn started her career as Assistant Professor of Clinical Pharmacy at the University of the Sciences in Philadelphia, where she currently holds the position of Dean's Professor. She received a Pharm.D. from the University of California, San Francisco, School of Pharmacy. She also received a Certificate of Professional Development from The Wharton School at the University of Pennsylvania.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain, psychiatry and women's health. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate), Erwinaze™ (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide intrathecal infusion), FazaClo® (clozapine USP) HD and LD, Luvox CR® (fluvoxamine maleate) and Elestrin® (estradiol gel 0.06%). Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by an international division, EUSA Pharma.
SOURCE Jazz Pharmaceuticals plc
Ami Knoefler, Executive Director, Investor Relations & Corporate Communications, Ireland, + 353 1 638 1032, U.S., + 1 650 496 2947
